StudyFinder

SUSTAINED RELEASE ORAL FORMULATION FOR TREATMENT OF PARKINSON'S DISEASE

Status: Recruiting

LD/CD (medications to treat Parkinson's disease) will be delivered using an assembly of nested sachets made of permeable material. The assembly is placed in the oral/buccal cavity (between cheek and gum of lower jaw) and delivers continuous release of CD and LD for both transmucosal and gastrointestinal absorption. The combination of CD/LD in the inner sachet varies from that in the outer sachet. This allows for sequential release of CD and then LD to mimic a CD pretreatment method which is known to increase LD absorption and prolong its half-life.

I'm interested

Sex: Male or Female
Age Group: 18 years and over
This study is also accepting healthy volunteers
Inclusion Criteria:

• Normal healthy
• 18-65 years of age
• Not currently taking medications regularly
• Able to fast 6 hours, only water allowed
Interventions:

Drug: levodopa/carbidopa oral formulation A, Drug: levodopa/carbidopa oral formulation B

Conditions:

Brain & Nervous System

Keywords:

Healthy adults

Study Contact: Khalaf Bushara - busha001@umn.edu
Principal Investigator: Khalaf Bushara
Phase: EARLY_PHASE1
IRB Number: STUDY00024501
See this study on ClinicalTrials.gov

Back